Boehringer Ingelheim's BiQi Zhuo monoclonal antibody has been approved for two indications.

On March 27, Borui Biopharmaceutical and Ustekinumab jointly announced that the biologic drug ustekinumab has been approved by the China National Medical Products Administration for dual indications on the same day. It is used to treat moderate to severe plaque psoriasis in adults suitable for systemic treatment or phototherapy, as well as to treat moderate to severe hidradenitis suppurativa in adults with inadequate response to conventional systemic treatment.